Q32 Bio Inc. (QTTB)
| Market Cap | 323.65M |
| Revenue (ttm) | 354,000 |
| Net Income (ttm) | -83.09M |
| Shares Out | 11.93M |
| EPS (ttm) | -32.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,129 |
| Open | 26.54 |
| Previous Close | 26.80 |
| Day's Range | 25.55 - 27.19 |
| 52-Week Range | 8.24 - 30.92 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 47.50 (+75.08%) |
| Earnings Date | May 9, 2024 |
About QTTB
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy... [Read more]
Financial Performance
In 2023, Q32 Bio's revenue was $1.16 million, a decrease of -63.97% compared to the previous year's $3.21 million. Losses were -$112.96 million, 2157.0% more than in 2022.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for QTTB stock is "Buy." The 12-month stock price forecast is $47.5, which is an increase of 75.08% from the latest price.
News
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
-- Completed enrollment in bempikibart alopecia areata (AA) Phase 2 clinical trial, with topline results expected in Q4'24; enrollment in bempikibart atopic dermatitis (AD) Phase 2 clinical trial rema...
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
WALTHAM, Mass. , April 3, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis...
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
-- Q32 Bio to focus on advancement of bempikibart (ADX-914) in ongoing atopic dermatitis (AD) and alopecia areata (AA) Phase 2 clinical trials and commencement of ADX-097 Phase 2 renal basket clinical...